Abstract
In the existing study focused on the solubility enhancement of lansoprazole by using solid dispersion technique. Lansoprazole is proton pump inhibitor (PPI). Lansoprazole is used for the treatment of gastric ulcer. Lansoprazole is the Class II Drug of Biopharmaceutical Classification system. By using novel solid dispersion methods to enhance the oral solubility of poor water-soluble drug. Lansoprazole has the low solubility and high permeability. Hence to enhance the solubility of lansoprazole we prepared the Lansoprazole solid dispersion (SD) with PVP K30, Poly Ethylene Glycol 6000 (PEG 6000) and Poloxamer 407. Lansoprazoledissolving tablet were formulated using various superdisintegrants like Crospovidone and Sodium Starch Glycolate by Direct compression. The prepared the tablet is evaluated at various parameters like weight variation, hardness, friability, disintegration time, drug content uniformity and In-vitro dissolution. The In-vitro Drug release study of solid dispersions SD6 show the high drug release around 98.93%. Overall, in the all formulations F12 which contains 6%, 3.75% and 10% of Crospovidone, SSG and MCC release the 98.93% drug is the best formulation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Research Journal of Pharmaceutical Dosage Forms and Technology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
